Relay Therapeutics Inc
RLAY3.705USD
+0.345+10.27%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
631.64MCap. mercado
PérdidaP/E TTM
Más Datos de Relay Therapeutics Inc Compañía
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
Información de la empresa
Símbolo de cotizaciónRLAY
Nombre de la empresaRelay Therapeutics Inc
Fecha de salida a bolsaJul 16, 2020
Director ejecutivoDr. Sanjiv K. Patel, M.D.
Número de empleados261
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 16
Dirección60 Hampshire Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02139
Teléfono16173708837
Sitio Webhttps://relaytx.com/
Símbolo de cotizaciónRLAY
Fecha de salida a bolsaJul 16, 2020
Director ejecutivoDr. Sanjiv K. Patel, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams
Mr. Brian R. Adams
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
173.28K
-8.97%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams
Mr. Brian R. Adams
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
173.28K
-8.97%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
7.68M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 18 de may
Actualizado: dom., 18 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
SB Investment Advisers (UK) Limited
16.28%
Point72 Asset Management, L.P.
6.32%
BlackRock Institutional Trust Company, N.A.
6.29%
Commodore Capital LP
5.83%
The Vanguard Group, Inc.
5.47%
Other
59.81%
Accionistas
Accionistas
Proporción
SB Investment Advisers (UK) Limited
16.28%
Point72 Asset Management, L.P.
6.32%
BlackRock Institutional Trust Company, N.A.
6.29%
Commodore Capital LP
5.83%
The Vanguard Group, Inc.
5.47%
Other
59.81%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
33.84%
Investment Advisor
30.76%
Private Equity
17.05%
Investment Advisor/Hedge Fund
15.09%
Sovereign Wealth Fund
3.37%
Research Firm
2.12%
Individual Investor
1.48%
Venture Capital
0.96%
Family Office
0.37%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
457
180.97M
105.56%
-7.64M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
2023Q2
397
136.32M
112.15%
-5.86M
2023Q1
398
137.34M
113.25%
-2.03M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
SB Investment Advisers (UK) Limited
27.90M
16.28%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
10.83M
6.32%
+9.23M
+579.77%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.79M
6.29%
-75.94K
-0.70%
Mar 31, 2025
Commodore Capital LP
10.00M
5.83%
+10.00M
--
May 08, 2025
The Vanguard Group, Inc.
12.08M
7.04%
-2.92M
-19.50%
Mar 31, 2025
Casdin Capital, LLC
9.10M
5.31%
+150.00K
+1.68%
Mar 31, 2025
Tang Capital Management, LLC
8.07M
4.71%
--
--
Mar 31, 2025
Bellevue Asset Management AG
7.38M
4.3%
--
--
Mar 31, 2025
Norges Bank Investment Management (NBIM)
5.78M
3.37%
+2.46M
+74.19%
Dec 31, 2024
State Street Global Advisors (US)
5.16M
3.01%
-120.53K
-2.28%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
TrueShares Technology, AI & Deep Learning ETF
0.47%
Tema Oncology ETF
0.42%
ALPS Medical Breakthroughs ETF
0.4%
JPMorgan Fundamental Data Science Small Core ETF
0.18%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
Avantis US Small Cap Equity ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.9%
TrueShares Technology, AI & Deep Learning ETF
Proporción0.47%
Tema Oncology ETF
Proporción0.42%
ALPS Medical Breakthroughs ETF
Proporción0.4%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.18%
SPDR S&P Biotech ETF
Proporción0.16%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.09%
Avantis US Small Cap Equity ETF
Proporción0.07%
ProShares Ultra Nasdaq Biotechnology
Proporción0.07%
Invesco Nasdaq Biotechnology ETF
Proporción0.07%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
